Trombetta, Claudia Maria
Piccini, Giulia
Pierleoni, Giulio http://orcid.org/0000-0001-8223-7201
Leonardi, Margherita
Dapporto, Francesca
Marchi, Serena
Andreano, Emanuele http://orcid.org/0000-0003-0088-5788
Paciello, Ida
Benincasa, Linda
Lovreglio, Piero
Buonvino, Nicola
Decaro, Nicola http://orcid.org/0000-0001-6348-7969
Stufano, Angela
Lorusso, Eleonora
Bombardieri, Emilio
Ruello, Antonella
Viviani, Simonetta http://orcid.org/0000-0002-3652-5082
Rappuoli, Rino http://orcid.org/0000-0002-8827-254X
Molesti, Eleonora
Manenti, Alessandro
Montomoli, Emanuele http://orcid.org/0000-0001-7595-4974
Article History
Received: 6 February 2022
Accepted: 16 August 2022
First Online: 2 September 2022
Competing interests
: G. Piccini, G. Pierleoni and A.M. are employed by VisMederi srl. M.L., F.D., L.B., E. Molesti are employed by VisMederi Research srl. R.R. is an employee of the GSK group of companies. E.A., I.P. and R.R. are listed as inventors of full-length human monoclonal antibodies described in Italian patent applications n. 102020000015754 filed on June 30th 2020, 102020000018955 filed on August 3rd 2020 and 102020000029969 filed on 4th of December 2020, and the international patent system number PCT/IB2021/055755 filed on the 28th of June 2021. All patents were submitted by Fondazione Toscana Life Sciences, Siena, Italy. E. Montomoli is an external consultant and Chief Scientific Officer of VisMederi srl and VisMederi Research srl.